中科微点-全球专利检索

  1. Login
  2. Sign Up

Search Results

74 records (took 0.047 seconds)

    Stabilized Trinder reagent
    5.
    发明授权
    Stabilized Trinder reagent 失效
    稳定的TRINDER试剂

    公开(公告)号：US5108733A

    公开(公告)日：1992-04-28

    申请号：US575206

    申请日：1990-08-30

    Applicant: Dario Frontini ,  Maurizio D'Alterio

    Inventor： Dario Frontini ,  Maurizio D'Alterio

    IPC: C12Q1/28

    CPC classification number: C12Q1/28

    Abstract: Spontaneous aspecific coloration in so-called Trinder reagents which can alter subsequent colorimetric determinations is inhibited by adding compounds of the chelating agent class to the solution. The resultant compositions contain a peroxidase enzyme, a phenylpyrazone derivative, a compound of phenolic or aromatic amine structure and a stabilizer. Preferred stabilizers are ethylenediaminetetraacetic acid (EDTA) and diethylenetriaminepentaacetic acid (DTPA).

    THROMBOSIS RISK TEST
    6.
    发明申请
    THROMBOSIS RISK TEST 审中-公开
    血栓风险测试

    公开(公告)号：WO1996042018A1

    公开(公告)日：1996-12-27

    申请号：PCT/US1996009036

    申请日：1996-06-06

    Applicant: INSTRUMENTATION LABORATORY, S.P.A. ,  CAMPBELL, Paula, A. ,  PREDA, Luigi

    Inventor： INSTRUMENTATION LABORATORY, S.P.A.

    IPC: G01N33/86

    CPC classification number: G01N33/86 ,  G01N2333/4626 ,  G01N2333/745 ,  G01N2333/96461 ,  G01N2333/96463 ,  G01N2405/04

    Abstract: The present invention provides a method for determining thrombotic risk in an individual. The method involves determining the activity of Protein C and Protein S in the plasma of the individual thought to be at thrombotic risk by adding to a plasma sample obtained from the individual: (i) a first reagent in an amount sufficient to induce or activate coagulation in the plasma, (ii) a second reagent which activates endogenous protein C in the plasma, and (iii) a third reagent comprising calcium salts, phospholipids or tissue thromboplastin, or a combination thereof. To a second plasma sample from the same subject is added a reagent which induces or activates coagulation, and a buffer or other material which does not activate protein C, and a third reagent as described above. The time, rate or both, necessary for the conversion of endogenous fibrinogen to fibrin in both the first and second samples is measured. The same steps are performed on normal control plasma, and the difference or ratio in the times, rates, or both, obtained above are determined. The difference or ratio is indicative of the thrombotic risk in the subject. A kit adapted to carry out the method also is the subject of the present invention. The methods and kits of the invention in other embodiments may comprise a first reagent comprising a synthetic substrate, a second reagent which in the first sample from the subject activates protein C, and in the second sample, a second reagent which does not activate protein C. In these embodiments, the rates of hydrolysis of the synthetic substrates are measured and compared.

    Abstract translation: 本发明提供了确定个体血栓形成风险的方法。 该方法包括通过加入从个体得到的血浆样品来确定被认为是血栓形成风险的个体的血浆中的蛋白C和蛋白S的活性：（i）足以诱导或激活凝血的量的第一试剂 在等离子体中，（ii）活化血浆中的内源蛋白C的第二试剂，和（iii）包含钙盐，磷脂或组织凝血激酶或其组合的第三试剂。 向来自相同受试者的第二血浆样品中加入诱导或活化凝血剂的试剂，以及不活化蛋白质C的缓冲液或其它物质，以及如上所述的第三试剂。 测量在第一和第二样品中将内源纤维蛋白原转化为纤维蛋白所需的时间，速率或两者。 对正常对照等离子体进行相同的步骤，并确定上述得到的时间，速率或二者的差异或比例。 差异或比例表明受试者的血栓形成风险。 适于实施该方法的套件也是本发明的主题。 在其它实施方案中，本发明的方法和试剂盒可以包括第一试剂，其包含合成底物，来自受试者的第一样品中的第二试剂激活蛋白C，而在第二样品中，第二试剂不会活化蛋白C 在这些实施方案中，测量和比较合成基材的水解速率。

    Protein C pathway screening test
    8.
    发明授权
    Protein C pathway screening test 失效
    蛋白C通路筛选试验

    公开(公告)号：US5780255A

    公开(公告)日：1998-07-14

    申请号：US488510

    申请日：1995-06-09

    Applicant: Luigi Preda

    Inventor： Luigi Preda

    IPC: G01N33/50 ,  C12Q1/56 ,  G01N33/86 ,  C12Q1/37 ,  C12N9/48 ,  C12N9/74

    CPC classification number: G01N33/86 ,  G01N2333/4626 ,  G01N2333/745 ,  G01N2333/96461 ,  G01N2333/96463 ,  G01N2405/04

    Abstract: The present invention provides a method for determining thrombotic risk in an individual. The method involves determining the activity of Protein C and Protein S in the plasma of the individual thought to be at thrombotic risk by adding to a plasma sample obtained from the individual (i) a first reagent in an amount sufficient to induce or activate coagulation in the plasma, (ii) a second reagent which activates endogenous protein C in the plasma, and (iii) a third reagent comprising calcium salts, phospholipids or tissue thromboplastin, or a combination thereof. To a second plasma sample from the same subject is added a reagent which induces or activates coagulation, and a buffer or other material which does not activate protein C, and a third reagent as described above. The time, rate or both, necessary for the conversion of endogenous fibrinogen to fibrin in both the first and second samples is measured. The same steps are performed on normal control plasma, and the difference or ratio in the times, rates, or both, obtained above are determined. The difference or ratio is indicative of the thrombotic risk in the subject. A kit adapted to carry out the method also is the subject of the present invention. The methods and kits of the invention in other embodiments may comprise a first reagent comprising a synthetic substrate, a second reagent which in the first sample from the subject activates protein C, and in the second sample, a second reagent which does not activate protein C. In these embodiments, the rates of hydrolysis of the synthetic substrates are measured and compared.

    Abstract translation: 本发明提供了确定个体血栓形成风险的方法。 该方法包括通过加入从个体获得的血浆样品（i）以足以诱导或激活凝血的量的第一试剂来确定被认为是血栓形成风险的个体血浆中的蛋白C和蛋白S的活性 血浆，（ii）激活血浆中的内源蛋白C的第二试剂，和（iii）包含钙盐，磷脂或组织凝血激酶或其组合的第三试剂。 向来自相同受试者的第二血浆样品中加入诱导或活化凝血剂的试剂，以及不活化蛋白质C的缓冲液或其它物质，以及如上所述的第三试剂。 测量在第一和第二样品中将内源纤维蛋白原转化为纤维蛋白所需的时间，速率或两者。 对正常对照等离子体进行相同的步骤，并确定上述得到的时间，速率或二者的差异或比例。 差异或比例表明受试者的血栓形成风险。 适于实施该方法的套件也是本发明的主题。 在其它实施方案中，本发明的方法和试剂盒可以包括第一试剂，其包含合成底物，来自受试者的第一样品中的第二试剂激活蛋白C，而在第二样品中，第二试剂不会激活蛋白C 在这些实施方案中，测量和比较合成基材的水解速率。

    Stable aqueous NADH reagent and kit
    9.
    发明授权
    Stable aqueous NADH reagent and kit 失效
    稳定的NADH水溶液试剂盒

    公开(公告)号：US5278044A

    公开(公告)日：1994-01-11

    申请号：US917789

    申请日：1992-07-20

    Applicant: Richard C. San George ,  Carol A. Adiletto

    Inventor： Richard C. San George ,  Carol A. Adiletto

    IPC: C12Q1/32 ,  C12Q1/00 ,  C12Q1/52

    CPC classification number: C12Q1/32 ,  C12Q1/008 ,  C12Q1/52 ,  Y10S435/81 ,  Y10S435/975 ,  Y10T436/107497

    Abstract: An aqueous coenzyme reagent composition contains NADH, a carbonate/bicarbonate buffer (with a pH of about 9.5-11) and water. Both NADH and the buffer are at low concentrations, e.g., about 2-5 mM for NADH and about 2-15 mM for carbonate/bicarbonate. When this coenzyme reagent is mixed with an enzyme reagent, the mixture achieves a neutral pH. The combination of high pH, low NADH concentration and low buffer concentration permit the aqueous reagent to be stored for extended periods at low temperatures without NADH degrading to form impurities which interfere with or inhibit enzyme activity, such as the activity of lactate dehydrogenase or malate dehydrogenase in an assay for ALT or AST.

    Abstract translation: 含水辅酶试剂组合物含有NADH，碳酸盐/碳酸氢盐缓冲液（pH约9.5-11）和水。 NADH和缓冲液均为低浓度，例如对于NADH为约2-5mM，碳酸盐/碳酸氢盐为约2-15mM。 当该辅酶试剂与酶试剂混合时，混合物达到中性pH。 高pH值，低NADH浓度和低缓冲浓度的组合允许水性试剂在低温下长时间保存而不NADH降解以形成干扰或抑制酶活性的杂质，例如乳酸脱氢酶或苹果酸脱氢酶的活性 在ALT或AST的检测中。

Patent Agency Ranking